Innoviva Forward P/E
The Forward P/E Ratio of Innoviva (INVA) as of Aug 16, 2026 is 6.26. In the previous year, Forward P/E Ratio was 72.56 — a change of -91.37% (lower).
Get this data via API
Financial Data API
Forward P/E
6.26
YoY
-91.37%
Last updated:
Forward P/E Ratio of Innoviva is 2026 6.26 . Forward P/E Ratio of Innoviva was 2025 72.56 . It decreases by -91.37% lower compared to the previous year.
Access this data via the Eulerpool API
Innoviva Stock analysis
What does Innoviva do? Innoviva Inc - An innovative story
Innoviva Inc is a US-based company specializing in the development and marketing of therapy and diagnostic products for respiratory diseases. The company was founded in 1996 under the name Theravance Inc and was renamed Innoviva Inc in 2016.
The story of Innoviva Inc began with the goal of developing innovative therapies for chronic respiratory diseases. Over the years, the company expanded and diversified its product portfolio. Today, Innoviva Inc is a leading provider of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Business model of Innoviva Inc
The business model of Innoviva Inc is based on the development of products for the treatment of respiratory diseases and collaboration with other pharmaceutical and biotech companies. The company licenses its products to partner companies, which distribute them in the market. This way, Innoviva Inc generates revenue from licensing fees and milestone payments.
Divisions of Innoviva Inc
Innoviva Inc is divided into three divisions: development, licensing, and financing.
The development division is responsible for researching and developing new therapy and diagnostic products. The company works closely with other pharmaceutical and biotech companies in this regard.
The licensing division is responsible for licensing products to partner companies. This includes negotiating license agreements and conducting clinical trials.
The financing division of Innoviva Inc is responsible for raising external capital. This includes issuing bonds and seeking investment.
Products of Innoviva Inc
Innoviva Inc has a wide range of therapy and diagnostic products for respiratory diseases. These include:
- RELVAR®/BREO® (Fluticasone furoate/Vilanterol) for the treatment of COPD and asthma
- ANORO® (Umeclidinium bromide/Vilanterol) for the treatment of COPD
- TRELEGY® (Fluticasone furoate/Umeclidinium bromide/Vilanterol) for the treatment of COPD
These products have been developed by Innoviva Inc and are licensed to partner companies for distribution.
Innoviva Inc is an innovative company specializing in the development and marketing of products for the treatment of respiratory diseases. The business model is based on the development of products and licensing them to partner companies. Innoviva Inc has a wide range of therapy and diagnostic products for respiratory diseases. Innoviva is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Innoviva stock
Forward P/E Ratio of Innoviva is 6.26 in 2026.
Forward P/E Ratio of Innoviva changed from 72.56 to 6.26, representing a -91.37% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Forward P/E Ratio Innoviva since 2006 – with annual values, charts, and detailed analysis.
The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.
To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Innoviva with sector peers and the industry average to assess whether it is attractive.
Access this data via the Eulerpool API
Valuation — Innoviva
All Key Metrics — Innoviva
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth